pharma · Arginase 1 deficiency (ARG1-D)
Immedica Pharma AB
Immedica Pharma AB is a pharma organization headquartered in Stockholm, SE. Primary therapeutic focus areas include Arginase 1 deficiency (ARG1-D). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 pat
Stockholm, SE HQ
2018 Founded
179 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, SE
- Founded
- 2018
- Employees
- 179
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Loargys 5 mg/ml solution for injection/infusion
Phase 3 · small molecule · Arginase 1 deficiency (ARG1-D)
Loargys 5 mg/ml solution for injection/infusion for Arginase 1 deficiency (ARG1-D) is a Phase 3 program (small_molecule) at Immedica Pharma AB with 1 ClinicalTrials.gov record(s).
Internal code CAEB1102-301A
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Immedica Pharma AB
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Arginase 1 deficiency (ARG1-D)
- Status
- active
- Trials
- 1